Certis Oncology Solutions is a life science technology company dedicated to precision oncology and translational science. Our mission is to connect every patient to the right cancer treatment, the first time, every time. Certis explores options for precision therapies beyond the current standard of care and partners with pharmaceutical companies to help develop the next generation of targeted therapeutics. The Certis Laboratory is CLIA-certified (#05D2149049) for high-complexity testing.
YOURPDX IS A FUNCTIONAL TEST THAT MEASURES THERAPEUTIC RESPONSE IN PERSONALIZED PATIENT-DERIVED XENOGRAFT MODELS. TEST RESULTS ARE NOT A REPLACEMENT FOR MEDICAL ADVICE. TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PATIENTS AND THEIR PHYSICIANS. YOURPDX TESTING REQUIRES FRESH TUMOR TISSUE. IT IS ESSENTIAL TO CONTACT US PRIOR TO BIOPSY OR RESECTION SURGERY. TESTIMONIALS APPEARING ON THIS SITE REFLECT REAL-LIFE EXPERIENCES OF THOSE WHO HAVE USED OUR SERVICES.
1 Strobl MAR, West J, Viossat Y et al. Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy. Cancer Res. 2021;81(4):1135-47. 2 Letai A, Bhola P, Welm A. Functional Precision Oncology: Testing Tumors with Drugs to Identify Vulnerabilities and Novel Combinations. Cancer Cell. 2022;49(1):26-35. 3 Napoli G, Figg WD, Chau C. Functional Drug Screening in the Era of Precision Medicine. Front. Med. 2022;9:912641. 4 Flaherty KT, Gray RJ, NCI-MATCH team et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. Nov. 20, 2020;38(33):3883-3894. 5 Napoli G, Figg WD, Chau C. Functional Drug Screening in the Era of Precision Medicine. Front. Med. 2022;9:912641. 6 Mamrot J et al. Predicting Clinical Outcomes Using Cancer Progression Associated Signatures. Oncotarget. 2021;12(8):845-858. 7 Celebi, R., Bear Don’t Walk, O., Movva, R. et al. In Silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data. Sci Rep. 2019;9:8949. 8 Jäger W, Xue H, Hayashi T, et al. Patient-Derived Bladder Cancer Xenografts in the Preclinical Development of Novel Targeted Therapies. Oncotarget. 2015;6(25):21522-21532. Wang X, Zhang H, Chen X. 9 Drug Resistance and Combating Drug Resistance in Cancer. Cancer Drug Resist. 2019;2:141-60. 10 Izumchenko, E, Paz, K, Ciznadija, D et al. Patient-Derived Xenografts Effectively Capture Responses to Oncology Therapy in a Heterogeneous Cohort of Patients with Solid Tumors. Annals of Oncology. 2017;28: 2595–2605.11 Walters DM, et al. Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens. PLoS One. 2013;8(10):e77065. 12 Das Thakur M et al. Modeling Vemurafenib Resistance in Melanoma Reveals a Strategy to Forestall Drug Resistance. Nature. 2013;494(7436):251-5.